argenx NV ADR (ARGX : NASDAQ)
Common Stock
$931.38
USD
+30.26 (3.36%)
Last updated: 2026-11-04
Follow ARGX
ARGX
argenx NV ADR
WealthAwesomePerformance
1 Day
+3.36%
1 Week
+4.44%
1 Month
+2.03%
YTD
+10.88%
Key Statistics
Market Cap
$56.67B
52W High
$1072.75
52W Low
$661.85
P/E Ratio
31.21
50 Day MA
$938.11
200 Day MA
$855.55
Beta
-0.07
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/4/2026 | $922.71 | $933.38 | $895.49 | $931.38 | $931.38 | 645,892 |
| 11/3/2026 | $874.09 | $903.27 | $873.32 | $901.12 | $901.12 | 432,225 |
| 11/2/2026 | $893.27 | $899.12 | $872.50 | $874.97 | $874.97 | 301,318 |
| 10/30/2026 | $896.79 | $916.05 | $890.01 | $892.87 | $892.87 | 462,400 |
| 10/29/2026 | $898.98 | $907.25 | $894.41 | $897.85 | $897.85 | 160,887 |
| 10/28/2026 | $873.08 | $897.03 | $870.21 | $891.76 | $891.76 | 193,373 |
| 10/27/2026 | $864.81 | $882.60 | $859.32 | $882.48 | $882.48 | 290,153 |
| 10/26/2026 | $876.46 | $884.18 | $864.11 | $869.33 | $869.33 | 269,569 |
| 10/23/2026 | $875.98 | $887.07 | $865.72 | $873.71 | $873.71 | 295,800 |
| 10/22/2026 | $853.28 | $897.27 | $853.28 | $875.76 | $875.76 | 1,020,771 |
Analyst Price Targets
Based on 23 analysts covering ARGX · as of Nov 2, 2026
Wall Street analysts forecast ARGX stock price to rise 23.2% over the next 12 months.
Consensus
Buy4.43 / 5.00
Avg. Target
US$1147.35
+23.2% Upside
Current Price
US$931.38
Last close
Analyst Breakdown (23 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ARGX's historical volatility
30-Day Vol
48.6%
Annualized
90-Day Vol
46.3%
Annualized
Trend (90d)
+31.2%
Annualized drift
90d Mean
US$1041.09
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$966.60 | US$817.37 – US$1143.08 |
| 60 trading days | US$1003.16 | US$791.35 – US$1271.65 |
| 90 trading days | US$1041.09 | US$778.65 – US$1391.99 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About argenx NV ADR
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Financials
- Revenue (TTM)
- $5.92B
- EBITDA
- $1.90B
- Profit Margin
- 31.73%
- ROE (TTM)
- 23.64%
- EPS (Diluted)
- 28.87
- Book Value
- 5.38
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About ARGX.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| INM | InMed Pharmaceuticals Inc | $17.50 | +941.67% |
| OMH | Ohmyhome Limited Ordinary Shares | $15.55 | +432.53% |
| CRIS | Curis Inc | $1.11 | +56.34% |
| PMAX | Powell Max Limited Class A Ordinary Shares | $1.04 | +54.07% |
| RFAIR | RF Acquisition Corp II Right | $0.24 | +50.00% |
| CRCT | Cricut Inc | $8.88 | +48.74% |
| LYEL | Lyell Immunopharma Inc | $15.43 | +43.27% |
| GENVR | Gen Digital Inc. Contingent Value Rights | $4.03 | +42.40% |
ARGX.US news timeline
7 articles covering ARGX.US, most recent first
LatestARGX vs INCY: which stock is the better value?
October 2026
- Argenx outlines ~$4B in 2026 OpEx and up to 5 U.S. launches in 2027
- A Week of Losses for argenx: What the Chart and the News Say
- argenx (ENXTBR:ARGX) Stock May Be Fully Priced After Its 185% Run
- ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study
- Why argenx NV ADR stock plummeted yesterday
- How Are Investors Reacting to argenx's Value Stock Comparison?